Global Information
회사소개 | 문의 | 비교리스트

일본뇌염 : 파이프라인 리뷰

Japanese Encephalitis - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 227543
페이지 정보 영문 46 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


일본뇌염 : 파이프라인 리뷰 Japanese Encephalitis - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 46 Pages

일본뇌염은 동물과 인간에게 감염되는 바이러스성 질환으로, 뇌주변의 막조직에 영향을 미치는 플라비바이러스에 의해 발생하며 모기에 의해 전염됩니다. 증상에는 발열, 두통, 근육통, 설사, 발작, 근력 저하 및 마비 등이 있습니다. 치료는 진통제 및 항경련제 등을 이용한 증상 완화를 목표로 하고 있습니다.

일본뇌염(Japanese Encephalitis)에 대한 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향 등의 정보를 정리하여 전해드립니다.

목차

서론

조사 범위

일본뇌염 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 개발중인 치료제 : 기업별
  • 개발중인 치료제 : 대학/기관별
  • 개발중인 제품 : 기업별
  • 개발중인 제품 : 대학/기관별

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • Ennaid Therapeutics LLC
  • Fab'entech SA
  • Indian Immunologicals Ltd
  • Kineta Inc
  • Livzon Pharmaceutical Group Inc
  • Panacea Biotec Ltd
  • Theravectys SA
  • Vaxine Pty Ltd
  • Zydus Cadila Healthcare Ltd

약제 개요

  • FDX-000
  • 일본뇌염 백신(11종류)
  • KIN-1400
  • Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections
  • Synthetic Peptides for Japanese Encephalitis

휴지 상태인 프로젝트

개발이 중지된 제품

부록

도표

LSH 17.05.22

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Japanese Encephalitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Japanese Encephalitis - Pipeline by Abivax SA, H1 2020
  • Japanese Encephalitis - Pipeline by Adimmune Corp, H1 2020
  • Japanese Encephalitis - Pipeline by BioNet- Asia Co Ltd, H1 2020
  • Japanese Encephalitis - Pipeline by Cadila Healthcare Ltd, H1 2020
  • Japanese Encephalitis - Pipeline by Ennaid Therapeutics LLC, H1 2020
  • Japanese Encephalitis - Pipeline by Fab'entech SA, H1 2020
  • Japanese Encephalitis - Pipeline by Indian Immunologicals Ltd, H1 2020
  • Japanese Encephalitis - Pipeline by Medigen Inc, H1 2020
  • Japanese Encephalitis - Pipeline by Shandong Hengye Biotech Co Ltd, H1 2020
  • Japanese Encephalitis - Pipeline by Sinovac Biotech Ltd, H1 2020
  • Japanese Encephalitis - Pipeline by Vabiotech, H1 2020
  • Japanese Encephalitis - Dormant Projects, H1 2020
  • Japanese Encephalitis - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Japanese Encephalitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Japanese Encephalitis - Pipeline Review, H1 2020, provides an overview of the Japanese Encephalitis (Infectious Disease) pipeline landscape.

Japanese encephalitis is a viral disease that infects animals and humans. It is caused by a flavivirus that affects the membranes around the brain. It is transmitted by mosquitoes. Symptoms include fever, headache, muscle pain, diarrhea, seizures, muscle weakness and paralysis. Treatment targets relief of symptoms like pain relievers and anticonvulsants.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Japanese Encephalitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Japanese Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Japanese Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Japanese Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Japanese Encephalitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Japanese Encephalitis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Japanese Encephalitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Japanese Encephalitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Japanese Encephalitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Japanese Encephalitis (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Japanese Encephalitis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Japanese Encephalitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Japanese Encephalitis - Overview
    • Japanese Encephalitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Japanese Encephalitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Japanese Encephalitis - Companies Involved in Therapeutics Development
    • Abivax SA
    • Adimmune Corp
    • BioNet- Asia Co Ltd
    • Cadila Healthcare Ltd
    • Ennaid Therapeutics LLC
    • Fab'entech SA
    • Indian Immunologicals Ltd
    • Medigen Inc
    • Shandong Hengye Biotech Co Ltd
    • Sinovac Biotech Ltd
    • Vabiotech
  • Japanese Encephalitis - Drug Profiles
    • ABX-196 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FDX-000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Japanese encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Japanese Encephalitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Japanese Encephalitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Japanese Encephalitis - Dormant Projects
  • Japanese Encephalitis - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q